Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer

Molecular Therapy Oncolytics

Volumn 2, Issue , 2015, Pages 15006-

  Freytag, Svend O ^a   Zhang, Yingshu ^a   Siddiqui, Farzan ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; FLUCYTOSINE; GAMMA INTERFERON; GANCICLOVIR; INTERLEUKIN 12; ONCOLYTIC ADENOVIRUS;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA REPLICATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG POTENCY; DRUG TOLERABILITY; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; HUMAN; HYPERTRANSAMINASEMIA; INTRAPROSTATIC DRUG ADMINISTRATION; LYMPHOCYTOPENIA; MALE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM CELL; PROTEIN BLOOD LEVEL; SUICIDE GENE; SUICIDE TRANSGENE;

EID: 85006117663     PISSN: None     EISSN: 23727705     Source Type: Journal    
DOI: 10.1038/mto.2015.6     Document Type: Article

References (26)

1. Russell, SJ, Peng, KW and Bell, JC (2012). Oncolytic virotherapy. Nat Biotechnol 30: 658-670.
2. Freytag, SO, Rogulski, KR, Paielli, DL, Gilbert, JD and Kim, JH (1998). A novel threepronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 9: 1323-1333.
3. Freytag, SO, Paielli, D, Wing, M, Rogulski, K, Brown, S, Kolozsvary, A et al. (2002). Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol Phys 54: 873-885.
4. Freytag, SO, Khil, M, Stricker, H, Peabody, J, Menon, M, DePeralta-Venturina, M et al. (2002). Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 62: 4968-4976.
5. Freytag, SO, Stricker, H, Pegg, J, Paielli, D, Pradhan, DG, Peabody, J et al. (2003). Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate-to high-risk prostate cancer. Cancer Res 63: 7497-7506.
6. Freytag, SO, Stricker, H, Peabody, J, Pegg, J, Paielli, D, Movsas, B et al. (2007). Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 15: 636-642.
7. Freytag, SO, Movsas, B, Aref, I, Stricker, H, Peabody, J, Pegg, J et al. (2007). Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther 15: 1016-1023.
8. Barton, KN, Stricker, H, Brown, SL, Elshaikh, M, Aref, I, Lu, M et al. (2008). Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther 16: 1761-1769.
9. Barton, KN, Stricker, H, Elshaikh, MA, Pegg, J, Cheng, J, Zhang, Y et al. (2011). Feasibility of adenovirus-mediated hNIS gene transfer and 131I radioiodine therapy as a definitive treatment for localized prostate cancer. Mol Ther 19: 1353-1359.
10. Freytag, SO, Stricker, H, Lu, M, Elshaikh, M, Aref, I, Pradhan, D et al. (2014). Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 89: 268-276.
11. Freytag, SO, Stricker, H, Movsas, B and Kim, JH (2007). Prostate cancer gene therapy clinical trials. Mol Ther 15: 1042-1052.
12. Freytag S, Stricker H, Movsas B, Elshaikh M, Aref I, Barton K et al. Gene therapy of prostate cancer. In: Roth JA (ed.). Gene-Based Therapies for Cancer. Springer, New York, 2010. pp. 33-49.
13. Freytag, SO, Barton, KN and Zhang, Y (2013). Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer. Gene Ther 20: 1131-1139.
14. Trinchieri, G (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146.
15. Del Vecchio, M, Bajetta, E, Canova, S, Lotze, MT, Wesa, A, Parmiani, G et al. (2007). Interleukin-12: biological properties and clinical application. Clin Cancer Res 13: 4677-4685.
16. Colombo, MP and Trinchieri, G (2002). Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13: 155-168.
17. Leonard, JP, Sherman, ML, Fisher, GL, Buchanan, LJ, Larsen, G, Atkins, MB et al. (1997). Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90: 2541-2548.
18. Atkins, MB, Robertson, MJ, Gordon, M, Lotze, MT, DeCoste, M, DuBois, JS et al. (1997). Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3: 409-417.
19. van Herpen, CM, Looman, M, Zonneveld, M, Scharenborg, N, de Wilde, PC, van de Locht, L et al. (2004). Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes. Clin Cancer Res 10: 2626-2635.
20. Sangro, B, Mazzolini, G, Ruiz, J, Herraiz, M, Quiroga, J, Herrero, I et al. (2004). Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 22: 1389-1397.
21. Alvarez, RD, Sill, MW, Davidson, SA, Muller, CY, Bender, DP, DeBernardo, RL et al. (2014). A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEIcholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol 133: 433-438.
22. Farah, H, Al-Atoom, A and Shehab, G (2012). Explanation of the decrease in alkaline phosphatase (ALKP) activity in hemolyzed blood samples from the clinical point of view: in vitro study. Jordan J Biol Sci 5: 125-128.
23. Paielli, DL, Wing, MS, Rogulski, KR, Gilbert, JD, Kolozsvary, A, Kim, JH et al. (2000). Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol Ther 1: 263-274.
24. Thomas, MA, Spencer, JF, La Regina, MC, Dhar, D, Tollefson, AE, Toth, K et al. (2006). Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 66: 1270-1276.
25. Schoenhaut, DS, Chua, AO, Wolitzky, AG, Quinn, PM, Dwyer, CM, McComas, W et al. (1992). Cloning and expression of murine IL-12. J Immunol 148: 3433-3440.
26. Schnell, MA, Hardy, C, Hawley, M, Propert, KJ and Wilson, JM (2002). Effect of blood collection technique in mice on clinical pathology parameters. Hum Gene Ther 13: 155-161.